The Alzheimer's Disease Research Center (ADRC) at Columbia University was established to courage and integrate research on the causes of Alzheimer's Disease (AD) and related age-related neurodegenerative diseases and to foster the development of improved diagnosis, prevention and treatment of these conditions. The Clinical Core and Neuropathology Core of the ADRC provide the patient and tissue resources for the examination of new diagnostic and treatment modalities and for biological investigation. The population of the Clinical Core is ethnically diverse with substantial numbers of White, Black and Hispanic patients. The integral research projects of the ADRC are focused on the molecular biology of dementia and on early changes in brain function in AD. These research projects are extended by a large number of independently funded projects on the dementias and their underlying biology which have been nucleated by the Center and draw on ADRC resources. The ADRC actively encourages research in all aspects of AD including caregiving, treatment and biology. The ADRC also serves and a source of education and information on AD. Through the efforts of Education and Information Transfer ore we provide a Web Page with both local and general information; training programs in the biology and psychology of aging; and extensive seminar and works- in-progress series; education for primary care physicians in care of AD patients and educational programs to the lay community. The ADRC offers research services for genotyping, DNA storage, cell line production and DNA sequencing and maintains a bank of appropriate tissues, DNA and cell lines to facilitate research in this and other research centers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG008702-14
Application #
6640834
Study Section
Special Emphasis Panel (ZAG1-PKN-7 (J1))
Program Officer
Phelps, Creighton H
Project Start
1989-09-29
Project End
2005-05-31
Budget Start
2003-06-15
Budget End
2004-05-31
Support Year
14
Fiscal Year
2003
Total Cost
$1,943,013
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Qureshi, Yasir H; Patel, Vivek M; Berman, Diego E et al. (2018) An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 38:
Reitz, Christiane (2018) Retromer Dysfunction and Neurodegenerative Disease. Curr Genomics 19:279-288
Tariciotti, Leonardo; Casadei, Matthew; Honig, Lawrence S et al. (2018) Clinical Experience with Cerebrospinal Fluid A?42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis 65:1417-1425
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Masucci, Michael D; Lister, Amanda; Corcoran, Cheryl M et al. (2018) Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort. J Nerv Ment Dis 206:356-361

Showing the most recent 10 out of 640 publications